TrianglePUBLICATIONS · 38452313
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2024 May 10
- First author
- Luke JJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Luke JJ
- type
- Author
- name
- Ascierto PA
- type
- Author
- name
- Khattak MA
- type
- Author
- name
- de la Cruz Merino L
- type
- Author
- name
- Del Vecchio M
- type
- Author
- name
- Rutkowski P
- type
- Author
- name
- Spagnolo F
- type
- Author
- name
- Mackiewicz J
- type
- Author
- name
- Chiarion-Sileni V
- type
- Author
- name
- Kirkwood JM
- type
- Author
- name
- Robert C
- type
- Author
- name
- Grob JJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Luke JJ
- type
- Author
- name
- Ascierto PA
- type
- Author
- name
- Khattak MA
- type
- Author
- name
- de la Cruz Merino L
- type
- Author
- name
- Del Vecchio M
- type
- Author
- name
- Rutkowski P
- type
- Author
- name
- Spagnolo F
- type
- Author
- name
- Mackiewicz J
- type
- Author
- name
- Chiarion-Sileni V
- type
- Author
- name
- Kirkwood JM
- type
- Author
- name
- Robert C
- type
- Author
- name
- Grob JJ
- type
- Author
- bibliography ids
- nci-bib-44181faff10eb0fe0936c556
- book metadata
- content sha256
- 4571c93bdf2a6f4045a94af3af105d01e98139172dce79272d9383e7019fba4d
- document type
- citation
- dois
- 10.1200/JCO.23.02355
- electronic publication date
- display
- 2024 Mar 7
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:38452313
- immutable id
- pubmed:38452313@4571c93bdf2a6f4045a94af3af105d01e98139172dce79272d9383e7019fba4d
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 14
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 1619-1624
- volume
- 42
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 38452313
- provenance
- batch id
- 6d213eecf21b6b7867cb
- provider
- NCBI PubMed ESummary
- record sha256
- 7c542bfc7bb2eeca1cd00d6d2d166dab64e31fc4efcf8b02d056d28023b883e4
- response sha256
- 684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
- retrieved at
- 2026-09-09T23:48:19.049083+00:00
- publication date
- display
- 2024 May 10
- precision
- day
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Preserved source evidence · Not medical advice